Testing DT-7012 in Advanced Solid Tumors
Treatments studied
Part of Cancer clinical trials.
This trial tests a new drug called DT-7012, given alone or with another immunotherapy, in people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if DT-7012 can shrink tumors or slow their growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your cancer must be an advanced solid tumor (it has spread or come back and can't be cured with standard treatments).
- You must have tried at least one type of standard cancer therapy that didn't work or stopped working.
- You need to have at least one tumor that can be measured on a CT or MRI scan and be able to have a biopsy (a small tissue sample taken from a tumor).
- You should be feeling generally well — able to do light activities like caring for yourself or doing housework (performance status 0 or 1).
- You cannot have had a previous severe immune reaction to immunotherapy that made you stop that treatment, and you cannot have taken an anti-CCR8 drug before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug combo (T3011 plus a PD-1/PD-L1 inhibitor) for people with advanced solid tumors that have not responded to other treatments. It aims to see if the combination can shrink tumors or slow their growth.
This early-phase trial tests a new drug (CD-001) for people with advanced solid tumors. It will check if the drug is safe, how the body handles it, and if it helps shrink tumors.
This trial tests a new pill called TT-702, either alone or with an immunotherapy drug, for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if it can help shrink or slow the growth of tumors.
This trial tests a new drug, CM518D1, for people with advanced solid tumors that have not responded to other treatments. It aims to see if the drug is safe and effective, and may offer a new option for those who have few choices left.
This trial tests an experimental drug (TEV‑56278) alone or with another drug (pembrolizumab) for people with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see if it helps shrink tumors.
This trial tests a new drug, BTM-3566, for people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and effective.
Hear when a new Advanced Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.